Skip Navigation

Europace 2003 5(2):123-131; doi:10.1053/eupc.2002.0295
© 2003 by European Society of Cardiology
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kale, M.
Right arrow Articles by Bennett, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kale, M.
Right arrow Articles by Bennett, D. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Pacemaker prevention therapies for the control of drug-refractory paroxysmal atrial fibrillation

M. Kale and D. H. Bennett

Regional Cardiac Centre, Wythenshawe Hospital Manchester, U.K.

AIMS: Atrial septal pacing has been shown to prevent paroxysmal atrial fibrillation (PAF) refractory to drugs in patients without inappropriate bradycardia. This study assesses the effects of atrial septal pacing using new pacing algorithms designed to prevent the initiation or maintenance of PAF.

METHODS AND RESULTS: Eleven Medtronic AT500 and 6 Guidant Pulsar Max pacemakers were implanted. The incremental benefit of prevention pacing therapies was compared with DDDR pacing by analysis of pacemaker-stored electrograms, ambulatory electrocardiography, symptoms and quality of life questionnaires.

RESULTS: Atrial septal pacing reduced AF burden by >50% in 13/17 patients (76·5%). Activation of a combined pacing algorithm (atrial pacing preference; atrial rate stabilization; and post mode-switch overdrive pacing) in patients with AT500 pacemakers produced a marginal reduction in AF burden (mean %AF 0·61 ON, 0·73 OFF, P=0·53 ns). Conversely in the Pulsar Max group when atrial pacing preference was activated, AF burden was slightly increased (mean %AF 5·84 ON, 3·73 OFF,P =0·13). Symptoms improved with atrial septal pacing but did not change when prevention algorithms were activated.

CONCLUSION: Atrial septal pacing resulted in a marked improvement in AF burden and symptoms. Activation of specific prevention pacing algorithms provided more continuous atrial pacing but had limited and heterogeneous effects on AF burden.

Key Words: Atrial septum, atrial fibrillation, preventive pacing for atrial fibrillation, atrial septal pacing

Correspondence: Dr M. Kale, Specialist Registrar Cardiology, Department of Cardiology, North Manchester General Hospital, Delaunays Road, Manchester, Delaunays Road, Crumpsall, Manchester, M8 5RB. Tel.: 0161 720 2579/2776; Fax: 0161 720 2741; E-mail: mkale{at}onetel.net.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EuropaceHome page
B. K. Kantharia, R. A. Freedman, D. Hoekenga, G. Tomassoni, S. Worley, R. Sorrentino, D. Steinhaus, J. M. Wolkowicz, Z. A. Syed, and and the AOP Study Investigators
Increased base rate of atrial pacing for prevention of atrial fibrillation after implantation of a dual-chamber pacemaker: insights from the Atrial Overdrive Pacing Study
Europace, November 1, 2007; 9(11): 1024 - 1030.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.